Bionomics start clinical trial for colorectal cancer patients

Company News

by Rachael Jones

The Australasian Gastro-Intestinal Trials Group is conducting a clinical trial with Bionomics (ASX:BNO) in combination with nivolumab.

The trial will enrol patients with advanced metastatic colorectal cancer at approximately 15 sites around Australia.

Biopharmaceutical company will enter phase II clinical trial of its cancer drug candidate, BNC105, in combination with Bristol-Myers Squibb’s nivolumab.

It's to test to see if the immune oncology drug can be used in combination with a vascular disrupting agent to treat patients that have exhausted all other options.

Shares in Bionomics (ASX:BNO) are trading 6.1 per cent higher at 10 cents.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.